Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal…

Overview of attention for article published in Journal of Clinical Oncology, January 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Nowa terapia dla pacjentów GIST

Termedia, 17 Feb 2025

lek.med. Sylwia Kopeć Data: 17.02.2025 Źródło: Trent J, Wagner A, Attia S, et al.

Agenus reports publication of data from bot/bal combination in JOCO

Markets Business Insider, 29 Jan 2025

Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in…

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Wall Street Online Denmark, 29 Jan 2025

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology…

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

OncLive, 28 Jan 2025

Cancer | Image Credit: © catalin - stock.adobe.com The combination of bezuclastinib (CGT9486) and sunitinib (Sutent) generated…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.